相似文献
1
In vitro activities of ramoplanin and four glycopeptide antibiotics against clinical isolates of Clostridium difficile.雷莫拉宁和四种糖肽类抗生素对艰难梭菌临床分离株的体外活性
Antimicrob Agents Chemother. 1991 Jan;35(1):195-7. doi: 10.1128/AAC.35.1.195.
2
In-vitro activity of vancomycin, teicoplanin, daptomycin, ramoplanin, MDL 62873 and other agents against staphylococci, enterococci and Clostridium difficile.万古霉素、替考拉宁、达托霉素、雷莫拉宁、MDL 62873及其他药物对葡萄球菌、肠球菌和艰难梭菌的体外活性。
J Antimicrob Chemother. 1990 Nov;26(5):627-33. doi: 10.1093/jac/26.5.627.
3
In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria.雷莫拉宁、替考拉宁、万古霉素、利奈唑胺、杆菌肽及其他四种抗菌药物对肠道厌氧菌的体外活性
Antimicrob Agents Chemother. 2003 Jul;47(7):2334-8. doi: 10.1128/AAC.47.7.2334-2338.2003.
4
5
In vitro activities of ramoplanin, selected glycopeptides, fluoroquinolones, and other antibiotics against clinical bloodstream isolates of gram-positive cocci.瑞莫拉宁、选定的糖肽类、氟喹诺酮类及其他抗生素对革兰氏阳性球菌临床血流分离株的体外活性。
Antimicrob Agents Chemother. 1993 Apr;37(4):896-900. doi: 10.1128/AAC.37.4.896.
6
Comparative in vitro activities of teicoplanin, daptomycin, ramoplanin, vancomycin, and PD127,391 against blood isolates of gram-positive cocci.替考拉宁、达托霉素、雷莫拉宁、万古霉素和PD127,391对革兰氏阳性球菌血液分离株的体外活性比较
Antimicrob Agents Chemother. 1992 Jul;36(7):1570-2. doi: 10.1128/AAC.36.7.1570.
7
Comparative in-vitro activity of vancomycin, teicoplanin, ramoplanin (formerly A16686), paldimycin, DuP 721 and DuP 105 against methicillin and gentamicin resistant Staphylococcus aureus.万古霉素、替考拉宁、雷莫拉宁（原A16686）、帕地霉素、DuP 721和DuP 105对耐甲氧西林和耐庆大霉素金黄色葡萄球菌的体外活性比较
J Antimicrob Chemother. 1989 Apr;23(4):517-25. doi: 10.1093/jac/23.4.517.
8
9
In vitro bactericidal activity of the glycopeptide compounds vancomycin, teicoplanin and ramoplanin (A-16686/MDL 62,198).
J Chemother. 1989 Jul;1(4 Suppl):210-1.
10
[Susceptibility of Clostridium difficile strains to teicoplanin and ramoplanin].
Med Dosw Mikrobiol. 1993;45(4):483-6.
引用本文的文献
1
infection: history, epidemiology, risk factors, prevention, clinical manifestations, treatment, and future options.感染：历史、流行病学、风险因素、预防、临床表现、治疗和未来选择。
Clin Microbiol Rev. 2024 Jun 13;37(2):e0013523. doi: 10.1128/cmr.00135-23. Epub 2024 Feb 29.
2
Novel Antimicrobials for the Treatment of Infection.用于治疗感染的新型抗菌药物。
Front Med (Lausanne). 2018 Apr 16;5:96. doi: 10.3389/fmed.2018.00096. eCollection 2018.
3
A Review of Experimental and Off-Label Therapies for Clostridium difficile Infection.艰难梭菌感染的实验性和非标签疗法综述
Infect Dis Ther. 2017 Mar;6(1):1-35. doi: 10.1007/s40121-016-0140-z. Epub 2016 Dec 1.
4
Generation of ramoplanin-resistant Staphylococcus aureus.耐雷普霉素金黄色葡萄球菌的产生。
FEMS Microbiol Lett. 2010 Sep 1;310(2):104-11. doi: 10.1111/j.1574-6968.2010.02051.x. Epub 2010 Jul 2.
5
In vitro activity of ramoplanin against Clostridium difficile, including strains with reduced susceptibility to vancomycin or with resistance to metronidazole.瑞莫拉宁对艰难梭菌的体外活性，包括对万古霉素敏感性降低或对甲硝唑耐药的菌株。
Antimicrob Agents Chemother. 2005 Mar;49(3):1157-9. doi: 10.1128/AAC.49.3.1157-1159.2005.
6
In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria.雷莫拉宁、替考拉宁、万古霉素、利奈唑胺、杆菌肽及其他四种抗菌药物对肠道厌氧菌的体外活性
Antimicrob Agents Chemother. 2003 Jul;47(7):2334-8. doi: 10.1128/AAC.47.7.2334-2338.2003.
7
Vancomycin-resistant enterococci.耐万古霉素肠球菌
Clin Microbiol Rev. 2000 Oct;13(4):686-707. doi: 10.1128/CMR.13.4.686.
8
Antimicrobial susceptibilities and serogroups of clinical strains of Clostridium difficile isolated in France in 1991 and 1997.1991年和1997年在法国分离出的艰难梭菌临床菌株的抗菌药敏性及血清群
Antimicrob Agents Chemother. 1999 Nov;43(11):2607-11. doi: 10.1128/AAC.43.11.2607.
9
Gastrointestinal tract colonization with vancomycin-resistant Enterococcus faecium in an animal model.动物模型中耐万古霉素屎肠球菌的胃肠道定植
Antimicrob Agents Chemother. 1996 Jun;40(6):1526-30. doi: 10.1128/AAC.40.6.1526.
10
Current perspectives on glycopeptide resistance.糖肽类耐药性的当前观点
Clin Microbiol Rev. 1995 Oct;8(4):585-615. doi: 10.1128/CMR.8.4.585.
本文引用的文献
1
Some chemical and physical characteristics of pantomycin, and antiobiotic isolated from Streptomyces hygroscopicus.泛霉素的一些化学和物理特性，一种从吸水链霉菌中分离出的抗生素。
Antimicrob Agents Chemother. 1980 Jun;17(6):980-7. doi: 10.1128/AAC.17.6.980.
2
In vitro activity of A-16686, a potential antiplaque agent.A-16686（一种潜在的抗牙菌斑剂）的体外活性
Antimicrob Agents Chemother. 1984 Oct;26(4):462-5. doi: 10.1128/AAC.26.4.462.
3
A-16686, a new antibiotic from Actinoplanes. II. Biological properties.
J Antibiot (Tokyo). 1984 Apr;37(4):318-24. doi: 10.7164/antibiotics.37.318.
4
A-16686, a new antibiotic from Actinoplanes. I. Fermentation, isolation and preliminary physico-chemical characteristics.
J Antibiot (Tokyo). 1984 Apr;37(4):309-17. doi: 10.7164/antibiotics.37.309.
5
Treatment of antibiotic-associated colitis with vancomycin.用万古霉素治疗抗生素相关性结肠炎。
J Antimicrob Chemother. 1984 Dec;14 Suppl D:97-102. doi: 10.1093/jac/14.suppl_d.97.
6
In vitro activity of teichomycin and vancomycin alone and in combination with rifampin.替考拉宁和万古霉素单独及与利福平联合使用时的体外活性。
Antimicrob Agents Chemother. 1983 Mar;23(3):402-6. doi: 10.1128/AAC.23.3.402.
7
Treatment of Clostridium difficile colitis.艰难梭菌结肠炎的治疗
Gastroenterology. 1985 Nov;89(5):1192-5. doi: 10.1016/0016-5085(85)90227-6.
8
In vitro activity of A-16686, a new glycopeptide.
Chemotherapy. 1986;32(5):453-7. doi: 10.1159/000238450.
9
Recovery of resistant enterococci during vancomycin prophylaxis.万古霉素预防期间耐万古霉素肠球菌的恢复情况。
J Clin Microbiol. 1988 Jun;26(6):1216-8. doi: 10.1128/jcm.26.6.1216-1218.1988.
10
In vitro evaluation of ramoplanin (MDL 62198, A 16686).瑞莫拉宁（MDL 62198，A 16686）的体外评估
Eur J Clin Microbiol Infect Dis. 1988 Dec;7(6):819-21. doi: 10.1007/BF01975062.
Zotero 插件